Abstract
Background and Aims Chronic kidney disease (CKD) significantly contributes to global morbidity and mortality. Early, targeted intervention offers an ideal strategy for mitigating this burden. Peptidomic changes inform on CKD onset and progression and hold insights for treatment strategies. We investigated the molecular effects of six different therapeutic interventions in silico in all possible combinations on the urine peptidome, aiming to identify the most beneficial treatment for individual patients.
Method This study predicted major adverse kidney events (MAKE), defined as a ≥40% decline in estimated glomerular filtration rate (eGFR) or kidney failure (median follow up time of 1.50 (95%CI 0.35, 5.0)), using the urinary peptidomic classifier CKD273 in a retrospective cohort of 935 participants. The impact of various treatments on urinary peptidomic profiles, assessed from previous studies of four different drug-based interventions (MRA, SGLT2i, GLP1-RA and ARB), one dietary intervention (olive oil) or from exercise, was applied. Treatment effects were quantified through fold changes in peptide abundance after treatment, recalibrated to align with outcomes observed in randomized controlled trials and applied to patient-specific urinary profiles, simulating intervention effects and recalculation of CKD273 scores for each individual. For combination treatments, the effects of multiple interventions were combined to model their cumulative impact.
Results Simulated interventions demonstrated a significant reduction in median CKD273 scores, from 0.57 (IQR: 0.19–0.81) before to 0.039 (IQR: -0.192–0.363) after intervention (paired Wilcoxon test, P < 0.0001), when the most beneficial treatment or combination of treatments was applied individually. The combination of all available treatments was found optimal only for 17.6% of the patients and not the most frequently predicted optimal intervention. Patients with higher baseline CKD273 scores required more complex intervention combinations to achieve the greatest reduction in scores. The findings present potential individualized treatment strategies in CKD management.
Conclusion This study supports the feasibility of in silico predicting effects of therapeutic interventions on CKD progression. By identifying the most beneficial treatment combinations for individual patients, this approach paves the way for precision medicine in CKD.
Urinary peptidomics data from different types of intervention were applied in silico to predict the impact of treatment, with the extent of the impact being calibrated to fit the observed effect in large randomized trials. The personalized optimal combination of interventions was determined in 935 patients, based on the impact on CKD273. The results indicate that guiding personalized treatment based on urine peptide data is possible and may substantially improve patient management.
Competing Interest Statement
Conflicts of Interest: HM is the founder and co-owner of Mosaiques Diagnostics (Hannover, Germany). AL, TMNN, IG, IM and AL are employed by Mosaiques Diagnostics. PR has received grants from Astra Zeneca. Bayer and Novo Nordisk and honoraria (to Steno Diabetes Center Copenhagen) from Astra Zeneca. Abbott. Bayer. Boehringer Ingelheim. Eli Lilly. Novo Nordisk. Gilead. and Sanofi. AO has received grants from Sanofi and consultancy or speaker fees or travel support from Adviccene. Alexion. Astellas. Astrazeneca. Amicus. Amgen. Boehringer Ingelheim. Fresenius Medical Care. GSK. Bayer. Sanofi-Genzyme. Menarini. Mundipharma. Kyowa Kirin. Lilly. Freeline. Idorsia. Chiesi. Otsuka. Novo-Nordisk. Sysmex and Vifor Fresenius Medical Care Renal Pharma and is Director of the Catedra UAM-Astrazeneca of chronic kidney disease and electrolytes. He has stock in Telara Farma. F.P. has served as a consultant on advisory boards or as an educator for Astra Zeneca, Novo Nordisk, Sanofi, Mundipharma, MSD, Boehringer Ingelheim, Novartis, and Amgen, and has received research grants to institution from Novo Nordisk, Amgen, and Astra Zeneca. All other authors have no potential conflicts of interest.
Funding Statement
This project was supported in part by the German ministry for education and science (BMBF) via UPTAKE (01EK2105A 01EK2105B) to HM JS and AL. Additional funding was provided by the ERA PerMed SIGNAL project (01KU2307) Accurate-CVD (ZIM KK5560002AP3) funded by the by the BMWK (Federal Ministry for Economic Affairs and Climate Protection), European Union Horizon 2020 research and innovation programme under grant agreement No 848011 for the DC-ren project and the European Union Horizon Europe Marie Skłodowska Curie Actions Doctoral Networks Industrial Doctorates Programme DisCo-1 (HORIZON MSCA 2021 DN, 101072828) and PICKED (HORIZON MSCA 2023 DN, 101168626). AO research is supported by FIS/Fondos FEDER ERA PerMed JTC2022 (SPAREKID AC22/00027). Comunidad de Madrid en Biomedicina P2022/BMD 7223. CIFRA COR CM. Instituto de Salud Carlos III (ISCIII) RICORS program to RICORS2040 (RD21/0005/0001) funded by European Union NextGenerationEU. Mecanismo para la Recuperacion y la Resiliencia (MRR) and SPACKDc PMP21/00109. FEDER funds. The project also received support from the COST Action PERMEDIK CA21165. supported by COST (European Cooperation in Science and Technology) and from the PREVENTCKD Consortium. Project ID: 101101220 Programme: EU4H. DG/Agency: HADEA. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the granting authorities. Neither the European Union nor the granting authority can be held responsible for them.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally published in Pharmaceuticals (Basel). 2023 Sep 14;16(9):1298. doi: 10.3390/ph16091298.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
